Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs 3M Company (MMM) Price & Performance

Mesoblast LimitedTrade
3M CompanyTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs 3M Company — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.16B), while 3M Company trades at $183.06 (market cap $93.88B). The key difference: 3M Company is far larger — about 43.5× Mesoblast Limited's market cap, and 3M Company pays a 1.71% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

MESOMMM
Market Cap
$2.16B$93.88B
Sector
TechnologyIndustrials
52-Week High
$20.96$183.13
52-Week Low
$12.88$141.10
Enterprise Value
$2.17B$103.10B
Dividend Yield
1.71%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

3M Company

3M (MMM) trades at $182.89, up 1.21% today, with a bullish technical signal from moving averages and strong support at $180. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.40 exceeding the $2.25 estimate, and raised its full-year guidance. Revenue for 2025 was $24.95 billion, with a net income margin of 11.9% and a high return on equity of 82.77%. Recent news highlights strength in the Safety & Industrial segment and a partnership with Microsoft on EBO technology.

The outlook is positive due to operational improvements and innovation, but risks include litigation liabilities and macroeconomic pressures. Analysts are mixed with a consensus price target of $173.00, below the current price, suggesting cautious optimism. The stock's valuation metrics, such as a P/E of 32.49, indicate it may be fully priced, requiring careful monitoring of execution against raised guidance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO

About 3M Company

3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.

Read more on MMM